Indeed, inhibition of DNA methylation by 5-aza-2′deoxycytidine (5-Aza) treatment increased the levels of LATS2 mRNA and protein in lumB-derived ZR75-1 cells (Fig 3A), suggesting that lumB breast cancers might undergo selective pressure to silence LATS2 expression. The gene discussed is LATS2; the disease is breast carcinoma.